PROMETHEUS BIOSCIENCES INC (RXDX)

US74349U1088 - Common Stock

199.92  +0.18 (+0.09%)

After market: 199.95 +0.03 (+0.02%)

Full profile views are only available for registered users, you can see which data is available below.

Examples of complete profiles are available for MSFT and AAPL.

Registered users have access to more data. Please register or login for additional data.

PROMETHEUS BIOSCIENCES INC

NASDAQ:RXDX (6/15/2023, 7:23:19 PM)

After market: 199.95 +0.03 (+0.02%)

199.92

+0.18 (+0.09%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
Chartmill FA Rating
Valuation
Growth
Profitability
Health
Dividend
Overview
Earnings (Last)
Earnings (Next)
Ins Owners
Inst Owners
Market Cap9.56B
Shares
PEN/A
Fwd PEN/A
Dividend YieldN/A
Analysts
IPO
Stock Screener Links
Screen Image

Nasdaq Stock Screener

Find more stocks on Nasdaq

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

GICS Sector Stock Screener

Find competitors from the same sector on the USA

Screen Image

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Growth Stock Screener

Find more growth stocks the USA

Screen Image

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Screen Image

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

RXDX Daily chart

Company Profile

Prometheus Biosciences, Inc. engages in operation of a biopharmaceutical company. The company is headquartered in San Diego, California and currently employs 97 full-time employees. The company went IPO on 2021-03-11. The firm discovers, develops and commercializes therapeutic products for the treatment of immune-mediated diseases, inflammatory bowel disease. Its precision medicine platform, Prometheus360, includes gastrointestinal bioinformatics databases and sample biobanks, to identify therapeutic targets, develop therapeutic candidates to engage those targets, and develop genetics-based diagnostic tests designed to identify patients to respond to its therapeutic candidates. Its lead product candidate, PRA023, is a humanized IgG1 monoclonal antibody (mAb) that has been shown to block the tumor necrosis factor (TNF). Its second product candidate, PRA052, is an anti-CD30L mAb. The CD30L-CD30 co-stimulatory pathway has been implicated in IBD by genetic, preclinical and human translational data. Its PR1100 program targets the receptor for a pro-inflammatory cytokine that has been linked to multiple immune-mediated diseases.

Company Info

PROMETHEUS BIOSCIENCES INC

3050 Science Park Road, #342

San Diego CALIFORNIA 92121

P: 18584224300.0

CEO: Mark C. McKenna

Employees: 97

Website: https://www.prometheusbiosciences.com/

RXDX News

News Image8 months ago - BloombergMerck Raises 2023 Sales Forecast as Cancer Drug Keytruda, Gardasil Vaccine Surge

Merck & Co.’s Keytruda and Gardasil soundly beat analysts’ estimates for quarterly sales, driving the company’s annual revenue forecast higher even as costs for its acquisition of Prometheus Biosciences Inc. led to a cut in its annual earnings outlook.

News Image9 months ago - The Motley FoolWhy Shares of Exscientia Jumped on Wednesday

The company may be riding the wave of an AI healthcare boom.

News Image9 months ago - The Motley FoolWhy Shares of Ventyx Biosciences Rose Monday

The company has several promising autoimmune therapies.

News Image9 months ago - The Motley FoolIs Merck Stock a Top Buy Right Now?

The drugmaker is still a work in progress.

News Image10 months ago - Market News VideoPrometheus Biosciences Moves Up In Market Cap Rank, Passing Bath & Body Works
News Image10 months ago - Halper Sadeh LLPSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates RXDX, RADI, FOCS

/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...

RXDX Twits

Here you can normally see the latest stock twits on RXDX, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example